You have reached an outdated page.
Please visit the Defeat Diabetes Foundation's new Web site at:
http://www.DefeatDiabetes.org
Defeat Diabetes: Rosuvastatin May Provide More Effective Lipid Lowering

Home

About Diabetes

Complications

Warning Signs

Screening Test

Donate Now

E-Lerts
Index

Latest News

Diabetes Terms

Health & Fitness

Online Press Center

Meet Mr. Diabetes®

Wake Up And Walk® Tour

Headlines & Stories

About Us - Contact Info

Message Board

Links

 

Rosuvastatin May Provide More Effective Lipid Lowering
posted 05/19/04
Switching to a more efficacious statin is an effective strategy to improve lipid goal achievement.

Rosuvastatin (Crestor) may be more effective than other statins in reduction of low-density lipoprotein cholesterol (LDL-C). Dr. Herbert Schuster of Humboldt University, Berlin, and colleagues note that rosuvastatin has already shown greater LDL-C reduction than other statins and they sought to extend these findings.

The researchers conducted an open-label study of 3140 hypercholesterolemic patients with coronary heart disease, atherosclerosis, or type 2 diabetes.

They were randomized to 8 weeks of treatment with rosuvastatin 10 mg, atorvastatin 10 mg or 20 mg, simvastatin 20 mg or pravastatin 40 mg. Patients then either remained on these treatments for a further 8 weeks or switched to rosuvastatin 10 or 20 mg.

The proportion of patients who reached the target level of LDC-L of less than 116 mg/dL at 16 weeks was significantly greater in those who switched to rosuvastatin 10 mg than in those remained on atorvastatin 10 mg (86% versus 80%).

There were similar findings in comparison with simvastatin 20 mg (85% versus 72%) and pravastatin 40 mg (88% versus 66%). This was also true of patients who switched to rosuvastatin 20 mg compared to those who remained on atorvastatin 20 mg (90% versus 84%).

The team notes that results were similar for European combined LDL-C and total cholesterol goals and for US LDL-C goals. All agents were well tolerated. Thus, the investigators conclude, "switching to a more efficacious statin is an effective strategy to improve lipid goal achievement."

AstraZeneca Plc, which sponsored this study, received approval from the US Food and Drug Administration to sell Crestor in August 2003.

Source: Diabetes In Control.com: Am Heart J 2004;147:705-712.

May News Article Index

Free Diabetes E-Lerts™ Newsletter:  Subscribe


   
To Change, Or Even Help Save The Lives Of Millions Of People,
Consider Making a Donation to Defeat Diabetes Foundation - Thank You! 

To be sure and come back to keep up with all the Latest News and important information for diabetics - and to remind yourself to manage and control your diabetes, click the yellow link below to add a small icon of our Defeat Diabetes® "Torch" logo to your desktop.  All you need to do after that is click on the "Torch" to open our website.  Remember, we're here for you!Add Us To Your Desktop! 

                                                                                                               

      We subscribe to the HONcode principles of the HON Foundation. Click to verify.We subscribe to the HONcode principles of the Health On the Net Foundation
Date of last update:  06/18/04
To contact Webmaster: webmaster@defeatdiabetes.org 

Translate this page into Spanish using FreeTranslation.com.

 © Copyright 2001 - 2004, Defeat Diabetes Foundation, Inc., All Rights Reserved